Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by Baylor1965on Jul 12, 2011 9:18am
435 Views
Post# 18821418

Good stuff

Good stuffVery positive:

"An unexpected and key new observation from this study was a substantial and significant increase in cell count number in the dentate gyrus region and specifically CA3 neuron population. Importantly, cell populations within the dentate gyrus and specifically CA neurons are thought to play a role in key memory functions in animals and man.Accompanying the maintenance of overall brain volume and these specific cell populations was a robust and statistically significant behavioral improvement which started after day 14 and that continued to improve beyond day 21."

Brilliant. Now let's get some SP action.

Baylor

Bullboard Posts